

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/808,681	FIGDOR ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Stephen L. Rawlings	1643	

**All Participants:**

(1) Stephen L. Rawlings.

(2) Jeremy M. Jay.

**Status of Application:** \_\_\_\_

(3) \_\_\_\_.

(4) \_\_\_\_.

**Date of Interview:** 15 September 2008

**Time:** \_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description: .

**Part I.**

Rejection(s) discussed:

*Art rejection over U.S. Patent No. 5,844,075-A*

Claims discussed:

1-4

Prior art documents discussed:

*U.S. Patent No. 5,844,075-A*

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner explained that an updated search and consideration of the prior art revealed that U.S. Patent No. 5,844,075-A teaches a peptide that is indistinguishable from the claimed peptide, such that it would be necessary reject the claims as being anticipated by this patent.